Efficacy and safety of twice-daily application of delgocitinib cream 20 mg/g for 6 weeks in subjects with active discoid lupus erythematosus.A phase 2a exploratory, randomised, double-blind, vehicle-controlled, within-subject, multi-centre trial.

EO Pharma A/S0 个研究点目标入组 45 人开始时间: 2019年4月26日最近更新: 2020年6月8日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 45

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Age 18-70 years.
•Histopathological findings (current or previous) consistent with clinical diagnosis of DLE.
•Unequivocal clinical diagnosis of 2 active DLE target lesions that are <6 months old and amenable for clinical evaluation. This includes lesions located on the scalp if they fulfil all lesion-specific eligibility criteria.
•Target lesion Investigator Global Assessment score of at least moderate (=3) at screening and baseline.
•Target lesion erythema score =2 at screening and baseline.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 40
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 5

排除标准

•Target lesion dyspigmentation score of 2 at screening or baseline.
•Target lesion scarring/atrophy score of 2 at screening or baseline.
•Target lesion scarring alopecia score of >0 in scalp lesions at screening or baseline.
•Medical history of systemic lupus erythematosus (SLE) with clinically significant organ involvement (American College of Rheumatology SLE classification criteria no. 6-9) including LE-related pleuritis or pericarditis (by clinical evaluation, i.e. no electrocardiogram or X-ray required), and neurologic, renal, and/or other major SLE-related organ system involvement. SLE joint involvement is acceptable.
•Subjects with unstable or significant SLE disease activity findings that would, by its progressive nature and/or severity, interfere with the trial evaluation, completion, and/or procedures per the investigator's discretion.
•Other skin conditions at screening or baseline that would interfere with the evaluation of DLE.
•Immunosuppressive/immunomodulating therapy with e.g. methotrexate, cyclosporine, azathioprine, retinoids (both topical and systemic), or dapsone within 4 weeks prior to baseline.
•Systemic prednisolone >7.5 mg/day or changed dose within 4 weeks prior to baseline (nasal and inhaled corticosteroids are allowed).
•Treatment with the following medications:
•Oral antimalarial treatment with hydroxychloroquine >6.5 mg/kg body weight/day, or chloroquine >4 mg/kg body weight/day, or changed dose within 12 weeks prior to baseline.
•Quinacrine combined with either hydroxychloroquine or chloroquine within 12 weeks prior to baseline.
•Drugs known to interact with antimalarials (e.g. digoxin, cimetidine) within 12 weeks prior to baseline.
•Treatment with topical corticosteroids, calcineurin inhibitors, and phosphodiesterase-4 (PDE-4) inhibitors within 2 weeks prior to baseline.
•Use of systemic antibiotics or cutaneously applied antibiotics on the target lesions within 2 weeks prior to baseline.
•Ultraviolet (UV) therapy within 2 weeks prior to baseline.
•Any procedure impairing the skin barrier (e.g. incision) within 2 cm from the border of any of the target lesions within 4 weeks prior to baseline.
•Receipt of live (attenuated) vaccines within 4 weeks prior to baseline.
•Treatment with any marketed biological therapy or investigational biologic agents:
•Any cell-depleting agents including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
•Other biologics: within 3 months or 5 half-lives, whichever is longer, prior to baseline.
•Smoking of >70 cigarettes/week or >70 g of tobacco content/week within 1 month prior to screening.
•History of any active skin infection within 1 week prior to baseline.
•Clinically significant infection within 4 weeks prior to baseline which, in the opinion of the investigator, may compromise the safety of the subject in the trial, interfere with evaluation of the IMP, or reduce the subject’s ability to participate in the trial. Clinically significant infections are defined as:
•A systemic infection.
•A serious skin infection requiring parenteral (intravenous or intramuscular) antibiotics, antiviral, or antifungal medication.
•Tuberculosis requiring treatment within 12 months prior to screening and/or subjects with a positive blood test for tuberculosis at screening. Subjects with high risk of latent tuberculosis (e.g. prior res

研究者

发起方

EO Pharma A/S

相似试验

进行中（未招募）

1 期

Efficacy and safety of delgocitinib cream in discoid lupus erythematosus.MedDRA version: 21.1Level: LLTClassification code 10013072Term: Discoid lupus erythematosusSystem Organ Class: 100000004858Discoid lupus erythematosus

EUCTR2018-003615-22-DEEO Pharma A/S45

进行中（未招募）

1 期

Efficacy and safety of delgocitinib cream in discoid lupus erythematosus.Discoid lupus erythematosusMedDRA version: 21.1Level: LLTClassification code 10013072Term: Discoid lupus erythematosusSystem Organ Class: 100000004858

EUCTR2018-003615-22-DKEO Pharma A/S45

进行中（未招募）

1 期

Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitusObesity

EUCTR2014-001540-38-GBovo Nordisk A/S957

进行中（未招募）

1 期

Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitusMedDRA version: 18.1Level: PTClassification code 10029883Term: ObesitySystem Organ Class: 10027433 - Metabolism and nutrition disordersObesity

EUCTR2014-001540-38-BEovo Nordisk A/S935

进行中（未招募）

1 期

Investigation of safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitusObesity

EUCTR2014-001540-38-DEovo Nordisk A/S935